(g) if so, the reasons therefor?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) Perhaps the reference is to Unstarred Question No. 1655 answered on 1st August, 1991 and not the one answered on 12th September, 1991. The details of liabilities of various companies and the amount deposited by each into the DPEA so far, are given in the Annexure: (*See* Appendix CLXL, Annexure No. 13).

(b) to (e) A number of companies were asked to discharge their entire liability failing which the Government will be constrained to process action for recovery of the amount as arrears of land revenue along with the interest from the date of default. A few of them have however, filed writ petition and obtained stay orders from the High Courts. Some of them have also asked for personal bearing and they are being heard.

(f) and (g) The matter is being looked into.

Position of DPSC

671. SHRI R. S. NAIK:
SHRIMATI SATYA BAHIN:

Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 1665 given in the Rajya Sabha on 12th September, 1991 and state:

(a) what is the position of DPRC Sub-Committee which works out the prices of formulations of drugs;

(b) whether DPRC belongs to BICP or is it an interministerial committee;

(c) who is the Chairman of the committee and to which organisation he belongs and what are the names of organisations to which each member of DPRC belongs;

(d) whether it is a fact that Chairman of the DPRC refused to consider the prices of formulations reduction based on notified reduced prices; and

(e) if so, names of the drugs whose prices were reduced during this year and the committee did not work for the reduction of formulation prices?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) and (b) DPRC Sub-Committee recommends the prices of drug formulations to the Government under DPCO, 1987 in accordance with a formula and fixed norms.

It is an Inter-Minsterial Committee.

(c) Member Finance, BICP is the Chairman of the DPRC Sub-Committee with members from the Department of Chemicals and Petrochemicals, Director General of Health Services (DGHS) and Directorate General of Technical Development (DGTD).

(d) and (e) The BICP had some difference of opinion as to the reduction in the prices of bulk drugs which was sorted out later. However, the scenario has changed after the exchange rate adjustment announced by the Government. As a result, prices of 9 out of 11 bulk drugs whose prices were reduced, have been revised upwards. In 4 cases, the revised prices are even more than the prerevised prices. The exercise to notify the prices of ceiling packs of formulations where the bulk drug price is still less than the pre reduced price is on hand.

Collecting data of drug Companies

672. SHRI R. S. NAIK:

SHRIMATI SATYA BAHIN:

Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 1654 given in the Rajya Sabha on the 12th September, 1991 and state:

(a) what are the names of companies which BICP addressed to collect date for study of conversion cost and packing charges;

(b) whether it is a fact that the copy of the communication was endorsed to Government;

(c) what are the names of the companies who have furnished the data so far;

(d) whether it is a fact that the norms already fixed by allowing 50 per cent increase are already very high and need to be reduced;

(e) what are the terms of reference of the committee and whether the existing norms are being reviewed;

(f) if so, what are the details;

(g) whether Government have taken any steps to pick up representative sample for this purpose; and

(h) if so, the details thereof?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) The names of companies to whom questionnaire was addressed by BICP is given in statement I (*See* below).

(b) Yes please.

(c) The names of the companies who responded are given in statement II (*See* below).

(d) It will be too early to comment as the study is under-way by the BICP.

(e) and (f) BICP has been asked to review the existing norms of conversion cost and packing charges by undertaking a comprehensive study *inter-alia* taking into account the escalation in the prices of petroleum.

(g) and (h) The companies selected for collection of data include representative companies from the organised sector, the public sector and companies with foreign equity.

Statement I

List of companies addressed for the Study of the norms for conversion cost and packing charges for pharmaceuticals formulations.

1. M/s. Indian Drugs & Pharmaceuticals Limited.
2. M/s. Hindustan Antibiotics Limited.
3. M/s. Bengal Chemicals & Pharmaceuticals Works Limited.
4. M/s. Bengal Immunity Co. Ltd.
5. M/s. U. P. Drugs & Pharmaceuticals Co. Limited.
6. M/s. Sendoz (India) Limited.
7. M/s. Torrent Pharmaceuticals.
8. M/s. Parke Davis (India) Limited.
9. M/s. Sarabhai Chemicals.
10. M/s. Cadila Laboratories.
11. M/s. Hoechst India Limited.
12. M/s. Glaxo Laboratories (India) Limited.
13. M/s Burroughs Wellcome (India). Limited.
14. M/s. East India Pharmaceuticals Works.
15. M/s. Hindustan Ciba-Geogy Limited.
16. M/s. Standard Organics Limited.
17. M/s. Ranbaxy Laboratories Pvt. Limited.
18. M/s. Alambic Chemicals Works Co. Limited.
19. M/s. Lupin Laboratories Limited.
20. M/s. Albert David Limited.
21. M/s. Astra IDL Ltd.
22. M/s. Dey's Medical Stores (P) Limited.
23. M/s. Chemical Industrial & Pharm-Lab. Limited.
24. M/s. Tamilnadu Dadha Pharmaceuticals Limited.
25. M/s. Unichem Laboratories Limited.
26. M/s. Lyke Labs. Ltd.
27. M/s. Eskay Limited.
28. M/s. Wockhardt Limited.
29. M/s. Merind Limited.
30. M/s. Rhono-Poulene (I) Ltd.

31. M/s. E. Merck (I) Limited.

32. M/s. Nicholas Laboratories India Limited.

33. M/s. Themis Laboratories (Pvt.) Limited.

34. M/s. Pfizer Limited.

35. M/s. Smith Stanistreet Pharmaceuti- Limited.

36. M/s. German Remedies Limited.

Statement II

List of companies from which information in part or in full have been received for the Study of the norms for CC/PC for Pharmaceutical formulations

1. M/s. Hindustan Antibiotics Ltd.

2. M/s. Bengal Chemicals & Pharmaceuticals Works Limited.

3. M/s. Cadila Laboratories

4. M/s. Burroughs Wellcome (India) Limited.

5. M/s. East India Pharmaceuticals Works.

6. M/s. Alembic Chemicals Works Co. Limited.

7. M/s. Dey's Medical Store P. Limited.

8. M/s. Lyka Labs. Limited.

9. M/s. Mcrind Limited.

10. M/s. Pfizer Limited.

11. M/s. Smith Stanistreet Pharmaceuticals Limited.

12. M/s. German Remedies Limited.

13. M/s. Sarabhai Chemicals.

Reduction of prices of drugs at consumer level

673. SHRI DHULESHWAR MEENA: SHRIMATI SATYA BAHIN:

Will the PRIME MINISTER be pleased to state:

(a) whether Government's attention has been drawn to the news item captioned "Delay in drug price revision hits health schemes" which appeared in the Business and Political Observer on 25th October, 1991;

(b) if so, what are the names of the drugs where Government have made efforts to reduce the prices at consumer level;

(c) what were the objection raised by BICP in not reducing the prices of medicines at consumer level; and

(d) when the recommendation from BICP was received in each case and when the price was notified and what steps were taken to reduce the prices at consumer level?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) Yes, Sir.

(b) to (d) There are eleven Scheduled Bulk Drugs whose prices have been reduced during this year. Before Government could notify the prices of ceiling packs of connected formulations on reduced prices of bulk drugs, there was change in Exchange rate of rupee against major foreign currencies. As a result, prices of nine out of these eleven bulk drugs have been revised upwards. In four cases, the revised prices are even more than the pre-revised prices. A Statement indicating the names of eleven bulk drugs, their pre-reduced prices, reduced prices and present prices with date is annexed (*See* below). The exercise to notify the prices of ceiling packs of formulations where the bulk drug price is still less than the pre-reduced price is on hand.